An Antiarrhythmic Effect of a Chymase Inhibitor after Myocardial Infarction

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 2, 2004, Pages 490-497

  Jin, Denan ^a   Takai, Shinji ^a   Sakaguchi, Masato ^a   Okamoto, Yukiko ^a   Muramatsu, Michiko ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (5 FLUORO 3 METHYLBENZO[B]THIOPHEN 2 YL)SULFONAMIDE 3 METHANESULFONYLPHENYL]OXAZOLE 4 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; CANDESARTAN; CHYMASE; CHYMASE INHIBITOR; TY 51184; UNCLASSIFIED DRUG;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REPRESSION; HAMSTER; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SUDDEN DEATH; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CHYMASES; DOGS; ENZYME INHIBITORS; HUMANS; MYOCARDIAL INFARCTION; OXAZOLES; SERINE ENDOPEPTIDASES; SULFONAMIDES;

EID: 2142656382     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.061465     Document Type: Article

References (37)

1. de Boer RA, van Geel PP, Pinto YM, Suurmeijer AJ, Crijns HJ, van Gilst WH, and van Veldhuisen DJ (2002) Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression. J Cardiovasc Pharmacol 39:610-619.
2. deGraeff PA, deLangen CD, van Gilst WH, Bel K, Scholtens E, Kingma JH, and Wesseling H (1988) Protective effects of captopril against ischemia/reperfusion-induced ventricular arrhythmias in vitro and in vivo. Am J Med 84:67-74.
3. de Langen CD, de Graeff PA, van Gilst WH, Bel KJ, Kingma JH, and Wesseling H (1989) Effects of angiotensin II and captopril on inducible sustained ventricular tachycardia two weeks after myocardial infarction in the pig. J Cardiovasc Pharmacol 13:186-191.
4. De Mello WC (1996) Renin-angiotensin system and cell communication in the failing heart. Hypertension 27:1267-1272.
5. De Mello WC (2001) Cardiac arrhythmias: the possible role of the renin-angiotensin system. J Mol Med 79:103-108.
6. De Mello WC and Crespo MJ (1999) Correlation between changes in morphology, electrical properties and angiotensin-converting enzyme activity in the failing heart. Eur J Pharmacol 378:187-194.
7. Frangogiannis NG, Lindsey ML, Michael LH, Youker KA, Bressler RB, Mendoza LH, Spengler RN, Smith CW, and Entman ML (1998) Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 98:699-710.
8. Harada K, Komuro I, Hayashi D, Sugaya T, Murakami K, and Yazaki Y (1998) Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias. Circulation 97:315-317.
9. Hirsch AT, Talsness CE, Schunkert H, Paul M, and Dzau VJ (1991) Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 69:475-482.
10. Hiura N, Wakatsuki T, Yamamoto T, Nishikado A, Oki T, and Ito S (2001) Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 38:729-736.
11. Hoshino F, Urata H, Inoue Y, Saito Y, Yahiro E, Ideishi M, Arakawa K, and Saku K (2003) Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 41 Suppl 1:S11-S18.
12. Jin D, Takai S, Yamada M, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, and Miyazaki M (2003) Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res 60:413-420.
13. Jin D, Takai S, Yamada M, Sakaguchi M, and Miyazaki M (2000) The functional ratio of chymase and angiotensin converting enzyme in angiotensin I-induced vascular contraction in monkeys, dogs and rats. Jpn J Pharmacol 84:449-454.
14. Jin D, Takai S, Yamada M, Sakaguchi M, and Miyazaki M (2002) Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci 71:437-446.
15. Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, and Miyazaki M (2001) Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol 86:203-214.
16. Levi R, Silver RB, Mackins CJ, Seyedi N, and Koyama M (2002) Activation of a renin-angiotensin system in ischemic cardiac sympathetic nerve endings and its association with norepinephrine release. Int Immunopharmacol 2:1965-1973.
17. Maruyama R, Hatta E, Yasuda K, Smith NCE, and Levi R (2000) Angiotensin-converting enzyme-independent angiotensin formation in a human model of myocardial ischemia: modulation of norepinephrine release by angiotensin type 1 and angiotensin type 2 receptors. J Pharmacol Exp Ther 294:248-254.
18. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, and Kinoshita M (2003) Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 107:2555-2558.
19. Miyazaki M and Takai S (2000) Role of chymase on vascular proliferation J Renin Angiotensin Aldosterone Syst 1:23-26.
20. Miyazaki M and Takai S (2001) Local angiotensin II-generating system in vascular tissues: the roles of chymase. Hypertens Res 24:189-193.
21. Nishimoto M, Takai S, Kim S, Jin D, Yuda A, Sakaguchi M, Yamada M, Sawada Y, Kondo K, Asada K, et al. (2001) Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 104: 1274-1279.
22. Passier RC, Smits JF, Verluyten MJ, Studer R, Drexler H, and Daemen MJ (1995) Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction. Am J Physiol 269:H1268-H1276.
23. Peach MJ (1997) Renin-angiotensin system: biochemistry and mechanism of action. Physiol Rev 57:313-370.
24. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669-677.
25. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582-1587.
26. Sakaguchi M, Yamamoto D, Takai S, Jin D, Taniguchi M, Baba K, and Miyazaki M (2001) Inhibitory mechanism of daphnodorins for human chymase. Biochem Biophys Res Commun 283:831-836.
27. Seyedi N, Koyama M, Mackins CJ, and Levi R (2002) Ischemia promotes renin activation and angiotensin formation in sympathetic nerve terminals isolated from the human heart: contribution to carrier-mediated norepinephrine release. J Pharmacol Exp Ther 302:539-544.
28. Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, Sakaguchi M, Matsumura E, Kim S, and Miyazaki M (2003a) A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3 -(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxyl-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 305:17-23.
29. Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K, and Miyazaki M (2001) Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta 305:191-195.
30. Takai S, Sakonjo H, Fukuda K, Jin D, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Miyazaki M (2003b) A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[, 4-dioxo-1-phenyl-7-(2-pyridyloxy)]2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther 304:841-844.
31. Takai S, Shiota N, Jin D, and Miyazaki M (1998) Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol 32:826-833.
32. Takai S, Shiota N, Yamamoto D, Okunishi H, and Miyazaki M (1996) Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci 58:591-597.
33. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, and Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251.
34. Tsunemi K, Takai S, Nishimoto M, Yuda A, Jin D, Sakaguchi M, Sawada Y, Asada K, Kondo K, Sasaki S, and Miyazaki M (2002) Lengthy suppression of vascular proliferation by a chymase inhibitor in dog grafted veins. J Thorac Cardiovasc Surg 124:621-625.
35. Urata H, Kinoshita A, Misono KS, Bumpus FM, and Husain A (1990) Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265:22348-22357.
36. Weber KT (1997) Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96:4065-4082.
37. Zhu B, Sun Y, Sievers RE, Browne AE, Pulukurthy S, Sudhir K, Lee RJ, Chou TM, Chatterjee K, and Parmley WW (2000) Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol 35:787-795.